January 11th, 2022 | 11:36 CET
Trading stocks in focus: BioNTech, Darktrace, EXMceuticals
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Security software is in demand
BioNTech, a biotech company based in Mainz, Germany, is currently the most frequently traded stock on Tradegate with over 1,500 trades at EUR 201.10 and a change of -0.64%. The share of cyber security company Darktrace has the highest gain on Tradegate with an increase of +18.75%. The shares last changed hands at EUR 5.70.
Will EXMceuticals become a SPAC?
Canadian company EXMceuticals announced after yesterday's close that the originally planned transaction with Global Cannabinoids had to be cancelled due to difficult conditions in the cannabis market. At the same time, Jonathan Summers is stepping down as CEO, but will remain on board as chairman of the company. Julie Lemieux has been named the company's new CEO to evaluate alternative business opportunities, according to the release. It sounds like EXMceuticals will be looking for a new use after commencing trading as a special purpose acquisition company (SPAC).
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as shareholders, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price development. In this context, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). The Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
Apaton Finance GmbH reserves the right to enter into paid contractual relationships with the company or with third parties in the future with regard to reports about the company that are reported on the Apaton Finance GmbH website as well as in social media, on partner sites or in e-mail messages.
The above information on conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications about companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.